Drilling Down on Interleukin-33
New Treatment Avenues for COPD and Acute Respiratory Infections
AN INTRODUCTION TO IL-33 SIGNALING
Tozorakimab to Prevent COPD Exacerbations
Sciurba FC, et al. N Engl J Med. 2026. doi: 10.1056/NEJMoa2606998. Online ahead of print.
Interleukin-33 (IL-33): a critical review of its biology and the mechanisms involved in its release as a potent extracellular cytokine.
Cayrol C, Girard JP. Cytokine. 2022;156(155981):1-15.
Reduction in exacerbations with itepekimab in former smokers with chronic obstructive pulmonary disease (COPD) by prior exacerbation frequency.
Rabe KF, et al. Eur Respir J. 2024;64(suppl 68):OA3645.
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.
Rabe KF, et al. Lancet Respir Med. 2021;9(11):1288-1298.
Targeting interleukin-33 and thymic stromal lymphopoietin pathways for novel pulmonary therapeutics in asthma and COPD
Calderon AA, et al. Eur Respir Rev. 2023;32(167):220144.
Involvement of IL-33 in the pathogenesis and prognosis of major respiratory viral infections: future perspectives for personalized therapy.
Murdaca G, et al. Biomedicines. 2022;10(3):715.
IL-33 and the cytokine storm in COVID-19: from a potential immunological relationship towards precision medicine.
Furci F, et al. Int J Mol Sci. 2022;23(23):14532.
Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.
Yousuf AJ, et al. Lancet Respir Med. 2022;10(5):469-477.
A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4.
Singh D, et al. Eur Respir J. 2025;66(1):2402231.
Late-Breaking Abstract. Randomised, placebo-controlled trial of astegolimab for COPD with frequent exacerbations: ALIENTO.
Greening N, et al. Eur Respir J. 2025;66(suppl 69).
Efficacy and safety of itepekimab in former smokers with chronic obstructive pulmonary disease: AERIFY-1 and AERIFY-2 Trials.
Rabe KF, et al. Presented at: American Thoracic Society (ATS) 2026 International Conference; May 15-20, 2026; Orlando, FL.
CLINICAL PRACTICE GUIDELINES
Global Strategy for Prevention, Diagnosis and Management of COPD: 2026 Report.
Global Initiative for Chronic Obstructive Lung Disease (GOLD).
Global Strategy for Asthma Management and Prevention: 2025.
Global Initiative for Asthma (GINA).
20
2026
Drilling Down on Interleukin-33
New Treatment Avenues for COPD and Acute Respiratory Infections
| Time: | 5:30 AM-7:30 AM PT |
| Venue: | Sheraton Phoenix Downtown (Phoenix Ballroom C) |
| Location: | Phoenix, AZ |
| Faculty: | Professor Tom Wilkinson, MA Cantab, MBBS, PhD, FRCP, FERS; Professor James Dodd, MBCHB, MRCP, PhD |
20
2026
Drilling Down on Interleukin-33
New Treatment Avenues for COPD and Acute Respiratory Infections
| Time: | 6:00 AM-7:30 AM PT |
| Venue: | Live Stream |
| Location: | Phoenix, AZ |
| Faculty: | Professor Tom Wilkinson, MA Cantab, MBBS, PhD, FRCP, FERS; Professor James Dodd, MBCHB, MRCP, PhD |
